19263-21-9

Basic information

• Product Name: BROMOETHYLTRIFLATE
• Synonyms: BROMOETHYLTRIFLATE;2-BroMo-ethyl tosylate;Ethanol, 2-bromo-, 1-(4-methylbenzenesulfonate)
• CAS NO: 19263-21-9
• Molecular Formula: C₉H₁₁BrO₃S
• Molecular Weight: 257.026
• Mol File: 19263-21-9.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BROMOETHYLTRIFLATE(CAS DataBase Reference)
• NIST Chemistry Reference: BROMOETHYLTRIFLATE(19263-21-9)
• EPA Substance Registry System: BROMOETHYLTRIFLATE(19263-21-9)

Safety Data

• Hazardous Substances Data: 19263-21-9(Hazardous Substances Data)

Usage

General Description

Bromoethyltriflate is a chemical compound with the molecular formula C4H5BrO3. It is a colorless to pale yellow liquid that is highly reactive and is commonly used as a reagent in organic synthesis. Bromoethyltriflate is a powerful alkylating agent, meaning it can transfer its ethyl group to other molecules, and is often used in the synthesis of pharmaceuticals and other organic compounds. It is also used as a reagent in the preparation of various functionalized compounds and as a potential precursor for the synthesis of alkylating agents. However, it is important to handle bromoethyltriflate with care, as it is highly toxic and can cause severe skin and eye irritation.

Upstream product

• 74-85-1 ethene 
• 104-15-4 toluene-4-sulfonic acid 
• 98-59-9 p-toluenesulfonyl chloride 
• 540-51-2 2-bromoethanol 
• 99142-43-5 N-(2-bromoethyl)-N-nitroso-4-methylbenzenesulfonamide 
• 107-04-0 1-Bromo-2-chloroethane 
• 80-48-8 methyl p-toluene sulfonate 
• 7182-86-7 tetrabutylammonium p-toluenesulfonate 

Downstream Products

• 1613033-36-5 methyl 2-(2-bromoethyloxybenzyl)-4-(cis-3a,4,5,6,7,7a-hexahydroisoindolin-2-yl)-4-oxobutanoate 
• 80-40-0 ethyl ester of p-toluenesulfonic acid 
• 113426-12-3 [(18)F]-2-fluoroethyltosylate 
• 85725-77-5 1-bromo-2-[¹⁸F]fluoroethane 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 5460-83-3 2-(1,3-dioxoisoindolin-2-yl)ethyl 4-methylbenzenesulfonate 
• 17046-84-3 1,4-bis-(toluene-4-sulfonyl)-piperazine 
• 762-49-2 2-fluoroethyl bromide 
• 111453-02-2 toluene-4-sulfonic acid-[N-(2-bromo-ethyl)-4-(4-nitro-phenylsulfanyl)-anilide] 

Relevant articles and documents

-

-

LOX INHIBITORS

The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use therefor for effectively treating and/or preventing FGFR-related diseases such as tumors

The present invention relates to an alkynyl-substituted heterocyclic compound serving as an FGFR inhibitor, a preparation method therefor and a medical use therefor. In particular, the present invention relates to a compound represented by the general formula (I) and its pharmaceutically acceptable salt, a pharmaceutical composition including the compound or its pharmaceutically acceptable salt, a method for treating and/or preventing FGFR-related diseases, particularly tumors, by using the compound or its pharmaceutically acceptable salt, and a preparation method of the compound or its pharmaceutically acceptable salt. The present invention also relates to an use of the compound or its pharmaceutically acceptable salt, or an pharmaceutical composition including the compound or its pharmaceutically acceptable salt in the preparation of a drug for treating and/or preventing FGFR-related diseases, particularly tumors, wherein the definition of each substituent in the general formula (I) is the same as that in the specification.

Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor

The N-Methyl-d-Aspartate receptor (NMDAR) is involved in many neurological and psychiatric disorders including Alzheimer's disease and schizophrenia. The aim of this study was to develop a positron emission tomography (PET) ligand to assess the bio-availa